Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jul 10;37(20):1732-1741.
doi: 10.1200/JCO.18.01799. Epub 2019 May 21.

Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study

Sally F Barrington  1 , Elizabeth H Phillips  2 , Nicholas Counsell  2 , Barry Hancock  3 , Ruth Pettengell  4 , Peter Johnson  5 , William Townsend  6 , Dominic Culligan  7 , Bilyana Popova  2 , Laura Clifton-Hadley  2 , Andrew McMillan  8 , Peter Hoskin  9   10 , Michael J O'Doherty  1 , Tim Illidge  10 , John Radford  10
Affiliations
Clinical Trial

Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study

Sally F Barrington et al. J Clin Oncol. .

Abstract

Purpose: Accurate stratification of patients is an important goal in Hodgkin lymphoma (HL), but the role of pretreatment clinical risk stratification in the context of positron emission tomography (PET) -adapted treatment is unclear. We performed a subsidiary analysis of the RAPID trial to assess the prognostic value of pretreatment risk factors and PET score in determining outcomes.

Patients and methods: Patients with stage IA to IIA HL and no mediastinal bulk underwent PET assessment after three cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine; 143 PET-positive patients (PET score, 3 to 5) received a fourth doxorubicin, bleomycin, vinblastine, and dacarbazine cycle and involved-field radiotherapy, and 419 patients in complete metabolic remission were randomly assigned to receive involved-field radiotherapy (n = 208) or no additional treatment (n = 211). Cox regression was used to investigate the association between PET score and pretreatment risk factors with HL-specific event-free survival (EFS).

Results: High PET score was associated with inferior EFS, before (P < .001) and after adjustment (P = .01) for baseline risk stratification. Only patients with a postchemotherapy PET score of 5 (uptake ≥ three times maximum liver uptake) had an increased risk of progression or HL-related death (hazard ratio, 9.4 v score of 3; 95% CI, 2.8 to 31.3 and hazard ratio, 6.7 v score of 4; 95% CI, 1.4 to 31.7). Patients with a PET score of 5 also had inferior progression-free and overall survival. There was no association between European Organisation for Research and Treatment of Cancer or German Hodgkin Study Group risk group and EFS, before or after adjusting for PET score (all P > .4).

Conclusion: In RAPID, a positive PET scan did not carry uniform prognostic weight; only a PET score of 5 was associated with inferior outcomes. This suggests that in future trials involving patients without B symptoms or mediastinal bulk, a score of 5 rather than a positive PET result should be used to guide treatment escalation in early-stage HL.

Trial registration: ClinicalTrials.gov NCT00943423.

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
CONSORT diagram. ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; CMR, complete metabolic response; IFRT, involved-field radiotherapy; NFT, no further treatment; PET, positron emission tomography.
FIG 2.
FIG 2.
Kaplan-Meier curves of (A) event-free survival (EFS), (B) progression-free survival (PFS), and (C) overall survival (OS) by positron emission tomography (PET) score.
FIG 3.
FIG 3.
Kaplan-Meier curves of event-free survival (EFS) by (A) European Organisation for Research and Treatment of Cancer (EORTC) and (B) German Hodgkin Study Group (GHSG) risk group.
FIG A1.
FIG A1.
Kaplan-Meier curves of event-free survival (EFS) by positron emission tomography score (PET) of 1 to 4 versus 5 for (A) EORTC favorable risk, (B) EORTC unfavorable risk, (C) GHSG favorable risk, and (D) GHSG unfavorable risk.
See this image and copyright information in PMC

Comment in

References

    1. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366:399–408. - PMC - PubMed
    1. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373:2499–2511. - PubMed
    1. Raemaekers JMM, Andre MPE, Federico M, et al: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188-1194, 2014. - PubMed
    1. Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): An open-label, randomised, non-inferiority trial. Lancet. 2015;385:1418–1427. - PubMed
    1. von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30:907–913. - PubMed

Publication types

MeSH terms

Associated data